Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:103969.
doi: 10.1155/2015/103969. Epub 2015 Mar 12.

Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology

Affiliations
Review

Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology

Shaobin Yu et al. Behav Neurol. 2015.

Abstract

Methamphetamine (METH) is a sympathomimetic amine that belongs to phenethylamine and amphetamine class of psychoactive drugs, which are widely abused for their stimulant, euphoric, empathogenic, and hallucinogenic properties. Many of these effects result from acute increases in dopamine and serotonin neurotransmission. Subsequent to these acute effects, METH produces persistent damage to dopamine and serotonin release in nerve terminals, gliosis, and apoptosis. This review summarized the numerous interdependent mechanisms including excessive dopamine, ubiquitin-proteasome system dysfunction, protein nitration, endoplasmic reticulum stress, p53 expression, inflammatory molecular, D3 receptor, microtubule deacetylation, and HIV-1 Tat protein that have been demonstrated to contribute to this damage. In addition, the feasible therapeutic strategies according to recent studies were also summarized ranging from drug and protein to gene level.

PubMed Disclaimer

References

    1. Panenka W. J., Procyshyn R. M., Lecomte T., et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug and Alcohol Dependence. 2013;129(3):167–179. doi: 10.1016/j.drugalcdep.2012.11.016. - DOI - PubMed
    1. Anglin M. D., Burke C., Perrochet B., Stamper E., Dawud-Noursi S. History of the methamphetamine problem. Journal of Psychoactive Drugs. 2000;32(2):137–141. doi: 10.1080/02791072.2000.10400221. - DOI - PubMed
    1. Kish S. J. Pharmacologic mechanisms of crystal meth. Canadian Medical Association Journal. 2008;178(13):1679–1682. doi: 10.1503/cmaj.071675. - DOI - PMC - PubMed
    1. Cisneros I. E., Ghorpade A. Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014;85:499–507. doi: 10.1016/j.neuropharm.2014.06.011. - DOI - PMC - PubMed
    1. Volkow N. D., Fowler J. S., Wang G.-J., et al. Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PLoS ONE. 2010;5(12) doi: 10.1371/journal.pone.0015269.e15269 - DOI - PMC - PubMed